IL143177A0 - Crystals of 5- [{6- (2-fluorobenzyl) oxy-2-naphthyl} methyl]-2,4-thiazolidinedione - Google Patents

Crystals of 5- [{6- (2-fluorobenzyl) oxy-2-naphthyl} methyl]-2,4-thiazolidinedione

Info

Publication number
IL143177A0
IL143177A0 IL14317799A IL14317799A IL143177A0 IL 143177 A0 IL143177 A0 IL 143177A0 IL 14317799 A IL14317799 A IL 14317799A IL 14317799 A IL14317799 A IL 14317799A IL 143177 A0 IL143177 A0 IL 143177A0
Authority
IL
Israel
Prior art keywords
fluorobenzyl
oxy
crystals
methyl
thiazolidinedione
Prior art date
Application number
IL14317799A
Other languages
English (en)
Original Assignee
Mitsubishi Chem Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chem Corp filed Critical Mitsubishi Chem Corp
Publication of IL143177A0 publication Critical patent/IL143177A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
IL14317799A 1998-11-20 1999-11-19 Crystals of 5- [{6- (2-fluorobenzyl) oxy-2-naphthyl} methyl]-2,4-thiazolidinedione IL143177A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP33054698 1998-11-20
PCT/JP1999/006492 WO2000031055A1 (en) 1998-11-20 1999-11-19 Chrystals of 5-[{6-(2-fluorobenzyl)oxy-2-naphthyl}methyl]-2,4-thiazolidinedione

Publications (1)

Publication Number Publication Date
IL143177A0 true IL143177A0 (en) 2002-04-21

Family

ID=18233859

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14317799A IL143177A0 (en) 1998-11-20 1999-11-19 Crystals of 5- [{6- (2-fluorobenzyl) oxy-2-naphthyl} methyl]-2,4-thiazolidinedione

Country Status (23)

Country Link
US (3) US6541493B1 (pt)
EP (1) EP1131310B1 (pt)
JP (1) JP3784001B2 (pt)
KR (1) KR100652326B1 (pt)
CN (1) CN1326449A (pt)
AT (1) ATE315552T1 (pt)
AU (1) AU1185100A (pt)
BR (1) BR9916795A (pt)
CA (1) CA2351727C (pt)
CZ (1) CZ20011763A3 (pt)
DE (1) DE69929476T2 (pt)
ES (1) ES2257104T3 (pt)
HU (1) HUP0104139A3 (pt)
ID (1) ID30064A (pt)
IL (1) IL143177A0 (pt)
NO (1) NO20012444L (pt)
NZ (1) NZ512429A (pt)
PL (1) PL348502A1 (pt)
PT (1) PT1131310E (pt)
TR (4) TR200202109T2 (pt)
TW (2) TWI250156B (pt)
WO (1) WO2000031055A1 (pt)
ZA (1) ZA200104081B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3784001B2 (ja) * 1998-11-20 2006-06-07 三菱化学株式会社 ５−［｛６−（２−フルオロベンジル）オキシ−２−ナフチル｝メチル］−２，４−チアゾリジンジオンの結晶体
BR0015702A (pt) * 1999-11-19 2002-07-16 Johnson & Johnson Formas de estado sólido de 5-[[6-[(2-fluorofenil)metoxi]-2naftalenil] metil] 2,4-tiazolidinediona
JP4590159B2 (ja) * 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法
WO2007049050A2 (en) * 2005-10-27 2007-05-03 Heptahelix Ab Modulators of gpr40 for the treatment of diabetes
PT2303267E (pt) * 2008-02-04 2013-08-05 Pfizer Ltd Forma polimórfica de um derivado de [1, 2, 4]triazol[4, 3-a]piridina para tratar doenças inflamatórias

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
JP2845743B2 (ja) * 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
JP4023697B2 (ja) 1996-11-14 2007-12-19 三菱化学株式会社 ナフタレン誘導体の製造方法
JP3784001B2 (ja) * 1998-11-20 2006-06-07 三菱化学株式会社 ５−［｛６−（２−フルオロベンジル）オキシ−２−ナフチル｝メチル］−２，４−チアゾリジンジオンの結晶体

Also Published As

Publication number Publication date
CA2351727C (en) 2008-09-23
TW200613291A (en) 2006-05-01
TR200101901T2 (tr) 2002-04-22
DE69929476D1 (de) 2006-04-06
PL348502A1 (en) 2002-05-20
TR200202110T2 (tr) 2002-10-21
NO20012444D0 (no) 2001-05-18
JP3784001B2 (ja) 2006-06-07
US6541493B1 (en) 2003-04-01
TWI272944B (en) 2007-02-11
US20030158241A1 (en) 2003-08-21
ATE315552T1 (de) 2006-02-15
KR20010101033A (ko) 2001-11-14
CZ20011763A3 (cs) 2001-10-17
TR200202103T2 (tr) 2002-11-21
BR9916795A (pt) 2002-04-09
HUP0104139A2 (hu) 2002-03-28
ZA200104081B (en) 2002-05-20
HUP0104139A3 (en) 2003-12-29
TWI250156B (en) 2006-03-01
TR200202109T2 (tr) 2002-11-21
AU1185100A (en) 2000-06-13
DE69929476T2 (de) 2006-09-14
JP2002530392A (ja) 2002-09-17
ID30064A (id) 2001-11-01
CA2351727A1 (en) 2000-06-02
WO2000031055A1 (en) 2000-06-02
NZ512429A (en) 2003-11-28
KR100652326B1 (ko) 2006-11-29
EP1131310A1 (en) 2001-09-12
EP1131310B1 (en) 2006-01-11
US20060149075A1 (en) 2006-07-06
ES2257104T3 (es) 2006-07-16
CN1326449A (zh) 2001-12-12
PT1131310E (pt) 2006-05-31
NO20012444L (no) 2001-07-18

Similar Documents

Publication Publication Date Title
HUP0203841A3 (en) 5-membered heteroaromatic compounds and use thereof for preparation of pharmaceutical compositions, and pharmaceutical compositions containing them
NZ336271A (en) Pharmaceutical compositions containing ziprasidone useful in treating psychosis
AU2002300661A1 (en) Method and compositions for the synthesis of BCH-189 and related compounds
ZA936306B (en) Imidazolidine derivatives
IL113084A0 (en) Thiazolidine and oxazolidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
YU36400A (sh) Supstituisani tiazolidinedion derivat, postupak za njegovo dobijanje i njegova farmaceutska primena
CA2130174A1 (en) 4-oxo-2 thioxoimidazolidine derivatives as inhibitors of blood platelet aggregation
HUP0103896A3 (en) Oxygenic heterocyclic compounds pharmaceutical compositions containing them and their use
MY135612A (en) Novel pharmaceutical
AP1441A (en) Hydrate of 5- [4-{2-(N-methlyl-N-(2-pyridil) amino) ethoxy} benzyl] thiazolidine-2,4-dione maleic acid salt.
IL143177A0 (en) Crystals of 5- [{6- (2-fluorobenzyl) oxy-2-naphthyl} methyl]-2,4-thiazolidinedione
IL95050A0 (en) 5-substituted 1,3,4-thiadiazole derivatives,and pesticidal compositions containing the same
DE3568333D1 (en) Novel 4,5-bis(4-methoxyphenyl)-2-(pyrrol-2-yl)thiazoles, process for the preparation thereof and pharmaceutical composition containing the same
AU5116590A (en) N-containing heterocyclic compounds, processes for the preparation thereof and composition comprising the same
ZA931593B (en) 2,4-Thiazolidinedione compounds, process for preparing them and pharmaceutical compositions containing them.
IL77051A (en) Crystalline form of the monoethanolamine salt of n-(2-pyridyl)-2-methyl-4-hydroxy-2h-1,2-benzothiazine-3-carboxamide 1,1-dioxide and pharmaceutical compositions containing it
EP0256507A3 (en) 3-(1h-tetrazol-5-yl)oxanilic acid and salts thereof, method for preparing the same and pharmaceutical compositions containing the compound
CA2319359A1 (en) Utilization of powder preparations containing hydroxypyridones for treating leg ulcers and decubitus ulcers
HUP9803041A3 (en) Thiazole derivatives, process for the preparation thereof, use thereof and pharmaceutical compositions containing them
NZ243552A (en) 2-[2-(4-methoxy-2-pyridinyl)phenylsulphinyl]-1h-benzimidazole derivatives, preparation and pharmaceutical compositions thereof
WO1993018059A3 (en) L-thiazolidine-4-carboxylic acid derivative, processes for the preparation thereof and the use thereof in therapy
HU9700106D0 (en) New 5-(amino-alkoxy-phenyl)-1,3,4-thiadiazol derivatives, process for producing them, and pharmaceutical compositions containing them as active component
IL115269A (en) Heterocyclic intermediate compounds for use in the preparation of oxazolidinedione and thiazolidinedione derivatives
AU6740187A (en) Heterocyclic compounds, methods for the manufacture of the same and pharmaceutical compositions containing the same
ZA973853B (en) New heterocyclic compounds having antidiabetic hypolipidaemic antihypertensive properties process for their preparation and pharmaceutical compositions containing them